期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Ciclopirox inhibits SARS-CoV-2 replication by promoting the degradation of the nucleocapsid protein
1
作者 Xiafei Wei Yuzheng Zhou +8 位作者 Xiaotong Shen Lujie Fan Donglan Liu Xiang Gao Jian Zhou yezi wu Yunfei Li Wei Feng Zheng Zhang 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2024年第6期2505-2519,共15页
The nucleocapsid protein(NP)plays a crucial role in SARS-CoV-2 replication and is the most abundant structural protein with a long half-life.Despite its vital role in severe acute respiratory syndrome coronavirus 2(SA... The nucleocapsid protein(NP)plays a crucial role in SARS-CoV-2 replication and is the most abundant structural protein with a long half-life.Despite its vital role in severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)assembly and host inflammatory response,it remains an unexplored target for drug development.In this study,we identified a small-molecule compound(ciclopirox)that promotes NP degradation using an FDA-approved library and a drug-screening cell model.Ciclopirox significantly inhibited SARS-CoV-2 replication both in vitro and in vivo by inducing NP degradation.Ciclopirox induced abnormal NP aggregation through indirect interaction,leading to the formation of condensates with higher viscosity and lower mobility.These condensates were subsequently degraded via the autophagy-lysosomal pathway,ultimately resulting in a shortened NP half-life and reduced NP expression.Our results suggest that NP is a potential drug target,and that ciclopirox holds substantial promise for further development to combat SARS-CoV-2 replication. 展开更多
关键词 SARS-CoV-2 Nucleocapsid protein Viral replication CICLOPIROX Abnormal aggregation Protein degradation Autophagy-lysosome Drug target
原文传递
Multiomics approach reveals the ubiquitination-specific processes hijacked by SARS-CoV-2 被引量:2
2
作者 Gang Xu yezi wu +9 位作者 Tongyang Xiao Furong Qi Lujie Fan Shengyuan Zhang Jian Zhou Yanhua He Xiang Gao Hongxiang Zeng Yunfei Li Zheng Zhang 《Signal Transduction and Targeted Therapy》 SCIE CSCD 2022年第10期3898-3910,共13页
The Coronavirus Disease 2019(COVID-19)caused by Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2)is a global pandemic that seriously threatens health and socioeconomic development,but the existed antiviral d... The Coronavirus Disease 2019(COVID-19)caused by Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2)is a global pandemic that seriously threatens health and socioeconomic development,but the existed antiviral drugs and vaccines still cannot yet halt the spread of the epidemic.Therefore,a comprehensive and profound understanding of the pathogenesis of SARS-CoV-2 is urgently needed to explore effective therapeutic targets.Here,we conducted a multiomics study of SARS-CoV-2-infected lung epithelial cells,including transcriptomic,proteomic,and ubiquitinomic.Multiomics analysis showed that SARS-CoV-2-infected lung epithelial cells activated strong innate immune response,including interferon and inflammatory responses.Ubiquitinomic further reveals the underlying mechanism of SARS-CoV-2 disrupting the host innate immune response.In addition,SARS-CoV-2 proteins were found to be ubiquitinated during infection despite the fact that SARS-CoV-2 itself didn’t code any E3 ligase,and that ubiquitination at three sites on the Spike protein could significantly enhance viral infection.Further screening of the E3 ubiquitin ligases and deubiquitinating enzymes(DUBs)library revealed four E3 ligases influencing SARS-CoV-2 infection,thus providing several new antiviral targets.This multiomics combined with high-throughput screening study reveals that SARS-CoV-2 not only modulates innate immunity,but also promotes viral infection,by hijacking ubiquitination-specific processes,highlighting potential antiviral and anti-inflammation targets. 展开更多
关键词 UBIQUITIN IMMUNITY DRUGS
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部